Condition: Rectum Cancer · Rectal Cancer · Sponsor: University Hospital, Geneva
This project investigates the clinical and biological impact of combining immunotherapy (pembrolizumab) with short course radiotherapy (5Gy, five times) in the neo-adjuvant treatment of localised microsatellite stable (MSS) rectal cancer.
This description comes directly from the study's public registry record.
Thibaud Kössler, MD PhD · +41 (0)22 372 77 68 · thibaud.kossler@hcuge.ch
Sandra Bettinelli Riccardi, PhD · +41223722903 · Sandra.BettinelliRiccardi@hcuge.ch
Always discuss trial participation with your own doctor first.
| Hôpitaux Universitaires de Genève | Geneva, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04109755